Evidence map›Paper›PMID 40165073›Full record

ArticleBMC pediatrics2025

Developing a quality indicator system for pediatric clinical trials management of research centers in China: a modified Delphi-Analytic Hierarchy Process study.

Chang Liu, Yi Liu, Bo Xuan, Yuenan Qi, Ling Ou, Jianmin Zhang

Abstract read
In one paragraph

Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chang LiuDrug Clinical Trial Institution, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Beijing, 100020, China. liuchangpumc@163.com.
Yi LiuDrug Clinical Trial Institution, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Beijing, 100020, China.
Bo XuanDrug Clinical Trial Institution, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Beijing, 100020, China.
Yuenan QiDrug Clinical Trial Institution, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Beijing, 100020, China.
Ling OuDrug Clinical Trial Institution, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Beijing, 100020, China.
Jianmin ZhangDrug Clinical Trial Institution, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Beijing, 100020, China. zhangjianm2023@163.com.

Funding

Beijing Hospitals Authority Youth Programme QML20231301Beijing Municipal Administration of Hospitals Incubating Program PZ20231302Capital's Funds for Health Improvement and Research 2022-2Z-2103National Key Research and Development Program 2022YFC3501901
6 · The paper itself

Abstract

backgroundPediatric clinical trials face many challenges that hinder the development of safe and effective pediatric drugs. Enhancing risk control and management quality of pediatric clinical trials in research centers is essential to address these challenges. While existing studies focus on risk management from the perspective of sponsors, research specifically addressing risk management strategies in research centers is limited. There is a lack of systematic exploration and expert consensus on risk-based management system of pediatric trials for institutions. This study seeks to fill this gap by developing a risk assessment index system designed to enhance the management quality of pediatric clinical trials in research centers. The system is built upon a theoretical framework that integrates insights from experts across various domains of pediatric clinical trials.

methodsThe Delphi-analytic hierarchy process method was used for expert consultation to develop a risk assessment index system in pediatric clinical trials management of research centers. The questionnaire was distributed to 20 experts with extensive experience in pediatric clinical trials. These experts were selected from various regions and work units across China. Experts with more than 5 years of working experience and bachelor degree or above were included for consultation. The mean value, proportion of experts with full marks, and variation coefficient of important score and feasibility score of the indicators were applied to include the indexes. The analytic hierarchy process was used to investigate the weight of each indicator.

resultsThe consultation outcomes exhibited good response rate and credibility, the experts' positive coefficients were 100% and 95%, respectively, and the authoritative coefficients were 0.885 and 0.892. The final quality management indicator system for research centers consisted of four primary, sixteen secondary, and thirty-two tertiary indicators. Protocol design and subject protection accounted for the highest weight of 0.3741 and 0.3148 respectively in the index system, and next came process management and data collection of 0.1879 and 0.1232 in quality management of pediatric clinical trials.

conclusionsThis study develops a systematic expert consensus on a risk-based quality system tailored to the management of pediatric clinical trials in domestic research centers. The framework identifies critical risk indicators in the management process, providing a potential reference for quality control and internal audits within pediatric clinical trial research centers in China. However, further research is required to assess its practical implementation and adaptability to diverse trial conditions.

Indexed as

Clinical Trials as TopicPediatricsQuality Indicators, Health CareRisk ManagementChildChinaDelphi TechniqueHumansRisk AssessmentAnalytic hierarchy processDelphi methodPediatric clinical trialResearch centerRisk management system

Identifiers

PMID40165073
PMCPMC11956244

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.